Today: 8 June 2026
Browse Category

NASDAQ:IBRX 29 November 2025 - 17 January 2026

ImmunityBio stock price surges on ANKTIVA sales pop — what IBRX investors watch next

ImmunityBio stock price surges on ANKTIVA sales pop — what IBRX investors watch next

ImmunityBio shares jumped 39.9% to $5.52 Friday after reporting a sharp rise in preliminary 2025 ANKTIVA sales and positive trial updates. The company projected about $113 million in 2025 net product revenue for ANKTIVA, up nearly 700% from 2024. An interim analysis showed higher complete response rates for ANKTIVA plus BCG in bladder cancer. U.S. markets reopen Tuesday after the MLK Jr. holiday.
17 January 2026
·
ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

ImmunityBio shares surged 35% Friday after reporting faster enrollment and positive interim results in its ANKTIVA bladder cancer trial. The company also disclosed $113 million in 2025 preliminary revenue and Saudi approval for ANKTIVA in lung cancer. Shares traded at $5.34 by midday with 133 million shares changing hands. Early data from its CD19 CAR-NK cell therapy showed complete responses in Waldenström lymphoma.
16 January 2026
···
Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

ImmunityBio shares jumped 16.5% to $4.60 Friday after the company reported $113 million in preliminary 2025 net product revenue from ANKTIVA and disclosed accelerated approvals in Saudi Arabia for lung and bladder cancer uses. Trading volume topped 56 million shares. Enrollment in the company’s pivotal bladder-cancer trial surpassed 85%, with FDA filing planned by late 2026.
16 January 2026
···
ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next

ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next

ImmunityBio shares rose 6.4% to $2.76 Tuesday after reporting new lung cancer trial data for its drug ANKTIVA. The company said ANKTIVA combined with checkpoint inhibitors restored immune-cell levels in two studies, with one showing longer median survival for patients with higher lymphocyte counts. A Phase 3 trial comparing ANKTIVA to docetaxel is ongoing. Fuller results are pending peer review.
13 January 2026
··
ImmunityBio (IBRX) Stock in Focus on Dec. 15, 2025: EMA’s ANKTIVA Nod, Analyst Targets, and What Comes Next

ImmunityBio (IBRX) Stock in Focus on Dec. 15, 2025: EMA’s ANKTIVA Nod, Analyst Targets, and What Comes Next

The European Medicines Agency’s CHMP issued a positive opinion recommending conditional marketing authorization for ImmunityBio’s Anktiva plus BCG in BCG-unresponsive non-muscle invasive bladder cancer. IBRX shares closed at $2.36 on Dec. 12, up 7.76% on heavy volume, and traded near $2.39 pre-market Dec. 15. The European Commission has not yet given final approval.
15 December 2025
··
ImmunityBio (IBRX) Stock Soars After Q3 Revenue Explosion – Can the Rally Survive a Going‑Concern Warning?

ImmunityBio (IBRX) Stock Soars After Q3 Revenue Explosion – Can the Rally Survive a Going‑Concern Warning?

ImmunityBio shares surged up to 13% on November 28 after reporting Q3 revenue of $32.1 million, up from $6.1 million a year earlier, driven by Anktiva sales. The company posted a Q3 net loss of $67.3 million and a nine-month cash outflow of $234.6 million. Anktiva is FDA-approved for certain bladder cancer patients in the U.S. and recently gained UK approval. Shares remain down mid-teens for the year.
29 November 2025
···
1 2

Stock Market Today

  • Nvidia Stock Forecast: Potential to Reach $300 by 2027 Amidst Strong AI-Driven Growth
    June 8, 2026, 5:00 PM EDT. Nvidia (NASDAQ: NVDA) posted a remarkable Q1 FY27 with revenue surging 85% year-on-year to $81.6 billion and free cash flow hitting $48.55 billion. Despite this, shares trade at $205.10, presenting a forward price-to-earnings (P/E) ratio of 26, below the 38x needed to reach $300 by 2027, per Wall Street's consensus target of $298. Nvidia's growth is propelled by AI infrastructure spending, with Q2 revenue guidance at $91 billion and $119 billion in supply commitments. Challenges include geopolitical issues in China and market sensitivity, but analyst sentiment remains 95% bullish. Our model predicts a $255 base case by mid-2027, reflecting 25% upside, while the $300 target requires significant earnings per share growth and multiple expansion. Nvidia remains a key player in AI and data center sectors.

Latest articles

IonQ Jumps as Quantum IPO Rush Sets Wall Street Benchmark

IonQ Jumps as Quantum IPO Rush Sets Wall Street Benchmark

8 June 2026
IonQ surged 10.5% to $62.77, outpacing quantum peers after Quantinuum’s $1.68 billion Nasdaq IPO gave investors a new benchmark for trapped-ion quantum stocks; IonQ’s rally follows its May guidance raise and soaring revenue, but losses and a long commercialization timeline remain key risks.
Snap Shares Climb as Debt Markets Send Signal

Snap Drops Again as Wall Street Stays Wary

8 June 2026
Snap plunged 2.1% to $5.64, underperforming a tech rebound, as investors weighed improved cash flow and a recent S&P credit upgrade against ongoing ad-market pressure, cost cuts, and spending on Specs; the stock’s weakness stood out as peers like Pinterest gained, highlighting market doubts about Snap’s ability to sustain growth amid tough competition and uncertain ad budgets.
Dow Drops After Hours, AI Rally Sidesteps Blue Chips

Dow Drops After Hours, AI Rally Sidesteps Blue Chips

8 June 2026
The Dow Jones fell 104.70 points, or 0.21%, to 50,762.08 as tech and chip stocks rebounded sharply, with the Philadelphia SE Semiconductor Index up 6.2% after Friday’s $1 trillion selloff; Apple dropped 1.4% despite its AI event, and investors now await Wednesday’s inflation data and Middle East energy risks as the next key tests for the market’s fragile rebound.
Nasdaq rises as AI names find support after market selloff

Nasdaq rises as AI names find support after market selloff

8 June 2026
Nasdaq surged 1.27% as investors snapped up AI and chip stocks after Friday’s rout, with the Philadelphia Semiconductor Index jumping 6.2%; Citigroup hiked its S&P 500 year-end target to 8,100 on AI demand, but Goldman Sachs warned strong jobs data makes a Fed rate hike more plausible, posing risks to growth stocks if inflation surprises.
Go toTop